0000000000142120

AUTHOR

Aymara Sancho-araiz

showing 2 related works from this author

The Role of Mathematical Models in Immuno-Oncology: Challenges and Future Perspectives

2021

Immuno-oncology (IO) focuses on the ability of the immune system to detect and eliminate cancer cells. Since the approval of the first immune checkpoint inhibitor, immunotherapies have become a major player in oncology treatment and, in 2021, represented the highest number of approved drugs in the field. In spite of this, there is still a fraction of patients that do not respond to these therapies and develop resistance mechanisms. In this sense, mathematical models offer an opportunity to identify predictive biomarkers, optimal dosing schedules and rational combinations to maximize clinical response. This work aims to outline the main therapeutic targets in IO and to provide a description …

0301 basic medicineOncologymedicine.medical_specialtyComputer scienceImmune checkpoint inhibitorsPharmaceutical ScienceCancer immunityReview03 medical and health sciences0302 clinical medicinePharmacy and materia medicaDosing schedulesInternal medicinemedicineTumor growthimmuno-oncologyPK/PD modelsPredictive biomarkertop-down approachMathematical modelPK/PDmathematical modelingRS1-441030104 developmental biologybottom-up approach030220 oncology & carcinogenesisSpitemiddle-out approachPharmaceutics
researchProduct

Semi-Mechanistic Model for the Antitumor Response of a Combination Cocktail of Immuno-Modulators in Non-Inflamed (Cold) Tumors.

2021

Simple Summary The clinical efficacy of immunotherapies when treating cold tumors is still low, and different treatment combinations are needed when dealing with this challenging scenario. In this work, a middle-out strategy was followed to develop a model describing the antitumor efficacy of different immune-modulator combinations, including an antigen, a toll-like receptor-3 agonist, and an immune checkpoint inhibitor in mice treated with non-inflamed tumor cells. Our results support that clinical response requires antigen-presenting cell activation and also relies on the amount of CD8 T cells and tumor resistance mechanisms present. This mathematical model is a very useful platform to ev…

AgonistCancer ResearchProgrammed cell deathmedicine.drug_classmedicine.medical_treatmentcold tumorscombination of therapeuticsArticleAntigenmedicinepreclinicalDoubling timeimmuno-oncologyRC254-282biologybusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensImmunotherapydrug developmentmechanistic modelingOncologyDrug developmentCancer researchbiology.proteinAntibodybusinessCD8Cancers
researchProduct